- Successful Coffee with a Cop at Murray Bridge SAPOL – Home
- We would like to thank everyone that came out to #CoffeeWithCops yesterday (1/9/26)! We love interacting with our community and having good conversations! #Culpeper #CommunityEngagement facebook.com
- El Paso Police Department Boosts Community Relations with ‘Coffee with a Cop’ Initiative Hoodline
- Coffee with a Cop: Fostering Community Connections in Rockport SouthTexasNews.com
- Coffee time with officers The Murray Valley Standard
Category: 3. Business
-
Successful Coffee with a Cop at Murray Bridge – SAPOL – Home
-
Concern ‘ghost stores’ taking advantage of Bondi massacre in online scam
An online fashion retailer accused of “unconscionable conduct” is under investigation for allegedly profiting off the Bondi terror attack.
NSW Fair Trading issued a public warning about “ghost store” Isla & James, which said it was holding a closure sale due to the mass shooting on December 14 and made “false claims” about being based in Bondi Beach.
The site claimed one of the co-founders, James, was “shot” in the massacre and there was no “moving on” after the shooting.
NSW Fair Trading Commissioner Natasha Mann said the agency now believed it was a “ghost store operating from overseas”.
“We think they’re using the Bondi Beach terror attack to really try and exploit the grief of our community to try and profiteer,” she said.
Samia Goudie was one of the customers who was duped by Isla & James last month, after coming across an emotionally-charged advertisement on Facebook.
They emphasised the business, once their “dream”, was closing down that night and the prices had been slashed so they could “start out [their] new lives”. The site also featured an an AI-generated image of the pair.
“Looking back, if it hadn’t had that emotional hook, I probably wouldn’t have looked at it,” she said.
Ms Goudie said she did “periphery checks” but the site looked “sophisticated”, with a map pinned to Bondi and a correlating Instagram page.
She spent $250 in her order, saying she did not “have the ability really to spend a lot of money” but wanted to support a good cause.
Samia Goudie wanted to show her support in the aftermath of the Bondi terror attack. (ABC News: Nicholas Haggarty)
Ms Goudie even emailed the store to express her sympathy and when they replied to say they were not closing down at all, the first red flag went off.
The order has not been sent out, and she later found out the items were likely from an e-commerce platform.
“The first reaction was, ‘How dare people do this?’ This is absolutely disgusting to use a tragedy to get people’s sympathy or empathy,”
she said.
“It wasn’t even like for myself, like, I’ve fallen for this. That was much later, you know, how stupid am I? … I felt like an idiot.
“It’s just a reminder to people … to double-check what they’re donating to.”
Concern others ‘may take similar approach’
The website appears to have been registered on December 23 from an IP address in Arizona, in the United States.
NSW Fair Trading said there was no contact number or trading address in the state, “nor any other evidence that the store is associated with a trader at Bondi Beach”.
Other warning signs for ghost stores can include no Australian address, no phone number or “.au” domain, or if the ABN cannot be verified.
Ms Mann is now warning the public about dealing with Isla & James, who she said may have engaged in a range of contraventions of Australian consumer law, including “misleading or deceptive conduct” and “unconscionable conduct in connection with the sale and supply of goods”.
She said ghost stores could claim to be closing down due to a tragedy to pressure people into buying goods, but were often selling low-quality goods or sometimes, nothing at all.
Ghost stores piggyback off of tragedies, like the Bondi terror attack, to lure in customers. (ABC News: Mary Lloyd)
“These ghost stores often are using really emotional stories to try and get consumers to rush into a purchase,” she said.
“The difficulty is that the operations are based overseas to avoid returns and refunds, which means that consumers are left in the lurch.”
Its website has now been taken down in a “welcome outcome”, but NSW Fair Trading has warned the retailer may crop up again under a different URL or “other traders may take a similar approach”.
“Our investigation will focus on making sure that this one remains shut down and actively monitoring to make sure that others do not arise also,” Ms Mann said.
“The main message to consumers is just really be vigilant when you’re engaging with online traders.”
Daniel Aghion says using deception off the back of the massacre was “callous”. (ABC News)
President of the Executive Council of Australian Jewry, Daniel Aghion, said at a time Jewish businesses were facing “victimisation and attacks” as well as closures, it was “callous that somebody somewhere in the world [was] trying to make money off the misery of others”.
“The idea that someone might try to profit from the massacre and do so by deception is just disgusting,”
Mr Aghion said.
“I feel for the shoppers that genuinely tried to support Bondi traders and victims of Bondi, but ended up being deceived.”
NSW Fair Trading has urged anyone who was not satisfied with their interaction with Isla & James to lodge a complaint with them or Service NSW.
It said any suspicious stores, fundraisers or offers linked to the Bondi attack should also be reported to Scamwatch.
Continue Reading
-
Infosys Receives 2025 AWS Sustainability Partner of the Year for EMEA
Infosys has been recognized as the 2025 AWS Sustainability Partner of the Year for the Europe, Middle East, and Africa (EMEA) region for demonstrating commitment and success in driving value for customers on their sustainability objectives. The recognition underscores Infosys’ ability to deliver innovative, AI- and cloud-powered solutions with Infosys Sustainability Cloud, harnessing Infosys Topaz™ and Infosys Cobalt™, that enable measurable environmental, social, and governance (ESG) impact and accelerate the transition to a low-carbon, resilient future.
The award was presented during the Partner Awards Gala at AWS re:Invent 2025. It honors AWS Partners that have demonstrated significant commitment to specialization, innovation, and collaboration through advanced solutions leveraging AI, ML, IoT, and data analytics.
Infosys was selected for its work with Economist Impact on The Sustainability Atlas, an AI-first platform designed to convert complex ESG data into clear, actionable insights for decision-makers. Powered by the integrated capabilities of Infosys Cobalt, Infosys Topaz, and AWS generative AI, the Sustainability Atlas offers clear and succinct responses to sustainability-related questions. It provides an efficient way to gain a holistic view of key sustainability themes, including climate resilience and social inclusion in different geographies around the world. The platform significantly reduces the time required for manual analysis, enabling enterprises and other users to shape effective strategies and policies based on data-driven insights.
The recognition highlights the collaboration between Infosys and AWS that is transforming data into actionable intelligence, driving meaningful progress in equity and sustainability. This award also reaffirms Infosys’ leadership in leveraging next-generation cloud and AI technologies to address global sustainability challenges and enable resilient, future-ready enterprises.
Continue Reading
-
Concorde commemorative 50p coin unveiled by Royal Mint
A new 50 pence coin celebrating 50 years since Concorde’s first commercial flight has been launched by the Royal Mint.
Unveiled at the aircraft’s current home, the Aerospace Bristol Museum, the reverse or ‘tails’ side of the coin portrays the aircraft in flight, against a backdrop of a split-flap departure board, with the word Concorde appearing across the centre.
The supersonic aircraft made its first commercial flight on 21 January 1976.
Former chief engineer of Concorde John Britton said: “To celebrate Concorde on an official UK coin is a proud moment for everyone who dedicated their careers to keeping her in the sky.”
Continue Reading
-
Share buyback program – 13 January 2026
Amsterdam, 13 January 2026 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 461,483 of its own shares in the period 5 – 9 January 2026 at an average price of €36.56. The total consideration of this repurchase was €16,873,986.
The total number of shares repurchased under this program to date is 4,141,810 shares for a total consideration of €158,797,681 at an average price of €38.34.
The repurchase is in accordance with the share buyback program to reduce the capital of Arcadis, as announced on 1 October 2025.
Overviews of all transactions under this program are published in weekly press releases and on the website of Arcadis.
Continue Reading
-
Innovation and Execution Power UCB’s Success
Brussels, Belgium – January 13, 2026– 7:00 CET – UCB (Euronext: UCB), a global biopharmaceutical leader committed to transforming the lives of people living with severe diseases, presents at the 44th Annual J.P. Morgan Healthcare Conference its powerful growth engine, innovation-led strategy, and the expanding global impact of BIMZELX®.
Turning Strategy into Results
UCB’s unwavering focus on innovation and execution excellence continues to deliver results. The company’s upgraded 2025 financial guidance underscores strong momentum and resilience, supported by a portfolio of five differentiated growth drivers —BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY® —each addressing significant unmet medical needs through unique mechanisms of action.
Jean-Christophe Tellier, CEO commented: “Our long-dated patent protection places us in a position of strength, underpinning resilience and enabling us to navigate uncertainty with confidence and agility. At the same time, BIMZELX® continues to expand its global footprint, having reached more than 100,000 patients worldwide —a clear validation of the recognized efficacy and differentiation of the assets. This reaffirms our intact decade-plus growth trajectory, driven by the excellence of our execution and the strength of our innovation.”
Key Highlights from the Presentation
- Financial Strength: Upgraded 2025 guidance (on December 5th, 2025) projects revenues exceeding €7.6 billion and an adjusted EBITDA margin above 31%, positioning UCB to deliver on its Decade+ growth strategy. 2025 financial results and the 2026 financial guidance will be announced on February 26, 2026.
- Breakthrough Innovation: U.S. approval of KYGEVVITM, first and only approved treatment for adult and pediatric patients with Thymidine Kinase 2 deficiency, launching in Q1 2026, reinforces UCB’s commitment to addressing unmet needs. Additionally, compelling data for galvokimig in atopic dermatitis further demonstrates pipeline strength.
- Expanded Access: 2026 BIMZELX® coverage in the U.S. has surged, adding 36 million additional patients —a +25% increase versus 2025— bringing commercial coverage above 80%, alongside broad access for Medicaid and Medicare beneficiaries.
Confidence in Sustained Growth
With a foundation of differentiated innovation, disciplined execution, and purpose-led performance, UCB is poised to deliver long-term value for patients, shareholders, and society.
The CEO’s presentation and webcast from the J.P. Morgan Healthcare Conference will be available on UCB’s Investor Relations section.
For further information, contact UCB:
Investor Relations
Antje Witte
T +32.2.559.94.14
email antje.witte@ucb.comSahar Yazdian
T +32.2.559.91.37
email mailto:sahar.yazdian@ucb.comCorporate Communications
Laurent Schots
T +32.2.559.92.64
Email laurent.schots@ucb.comAbout UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statements
This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.
UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Continue Reading
-
ASX clocks best session of new year as miners charge
Australia’s sharemarket has surged to nine-week highs on the back of strong commodity prices and a rebound in the heavyweight financials sector, lifting the leading indices.
The S&P/ASX200 gained 62.6 points on Tuesday, up 0.71 per cent, to 8,822, as the broader All Ordinaries advanced 58.6 points, or 0.5 per cent, to 9,138.5.
Only four of 11 local sectors ended the session higher, but solid gains in the materials and financials sectors launched the market to its best day of the year so far.
The Australian dollar was buying 67.11 US cents, up from 66.98 US cents on Monday at 5pm.
Continue Reading
-
Intra-day update: rupee registers gain against US dollar – Business Recorder
- Intra-day update: rupee registers gain against US dollar Business Recorder
- Rupee registers gain against US dollar Business Recorder
- Foreign exchange rates in Pakistan for today, January 13, 2026 Profit by Pakistan
- Today Open Market Currency Rates in Pakistan – Dollar, Euro, Dirham, Riyal – 12 Jan 2026 Daily Pakistan
- Rupee gains one paisa against dollar Daily Times
Continue Reading
-
PQ on Strengthening Protection for Consumers Who Purchase High Value Packages from Businesses with Knowledge of Their Insolvency
Question:
Mr Alex Yeo: To ask the Deputy Prime Minister and Minister for Trade and Industry in view of the recent closure of a health product and foot reflexology business (a) whether the Ministry has plans to strengthen consumer protection measures for consumers who purchase high value packages from businesses that have knowledge that they are or will become insolvent; and (b) whether the Ministry will consider taking further action against the executives or directors of such companies.
Written Answer by Deputy Prime Minister and Minister for Trade and Industry Gan Kim Yong
1. Under the Consumer Protection (Fair Trading) Act 2003 (CPFTA), it is an unfair practice for a supplier to exert undue pressure or influence on a consumer to enter into a transaction, or to accept payment for goods or services when the business knows that it will not be able to supply the goods or services. The Competition and Consumer Commission of Singapore can take enforcement action against such egregious suppliers. Consumers who encounter these unfair practices may approach the Consumers Association of Singapore (CASE) to seek redress.
2. The Government also works with CASE to empower consumers and help them make informed purchase decisions. In addition, CASE has a scheme that accredits businesses committed to fair trading practices and claims on unused prepayments in the event of business closure. Consumers are encouraged to engage CaseTrust-accredited businesses where applicable, especially when transactions involve significant prepayments.
3. In March 2025, the Government convened an independent Consumer Protection Review Panel led by CASE President Melvin Yong and former judicial commissioner Ms Foo Tuat Yien to review key consumer concerns, including the adequacy of existing protections for high-value package purchases. The Panel, comprising industry stakeholders, legal representatives and academics, is expected to publish its findings and recommendations later this year. The Government will study the Panel’s recommendations and consider the necessary additional measures.
Continue Reading
-
Written reply to PQ on Supporting SMEs to Adapt to Global Emphasis on Sustainability and Green Technologies
Question:
Mr Lee Hong Chuang: To ask the Deputy Prime Minister and Minister for Trade and Industry (a) what further measures, if any, will the Ministry be taking to support small- and medium-sized enterprises (SMEs) adapt to the growing global emphasis on sustainability and green technologies; and (b) what further plans does the Ministry have, if any, to help these SMEs remain competitive in international markets while meeting environmental standards.
Written Answer by Deputy Prime Minister and Minister for Trade and Industry Gan Kim Yong
1. The Government is committed to supporting our businesses, including SMEs, to prepare for a low-carbon economy and address the opportunities from rising demand in green technologies, products and services.
2. In May last year, EnterpriseSG launched the SME Sustainability Hub, a one-stop digital platform to help SMEs access relevant support and resources as they navigate their sustainability journey. The key resources available for SMEs include:
a. Assistance to meet the environmental requirements and standards of financial institutions and corporate customers. For example, the SME Sustainability Reporting Programme (SRP) and Sustainability Reporting Grant (SRG) are schemes that help SMEs build foundational sustainability reporting capabilities.
b. Training and capability-building programmes – Under the Enterprise Sustainability Programme (ESP), SMEs can access a series of sustainability playbooks and training courses on key topics, including decarbonisation and sustainable finance.
c. Funding support – For example, the Enterprise Development Grant (EDG) supports SMEs in developing sustainability strategies, products and services, and adopting green technologies to grow their businesses.
3. The Government is working closely with the Trade Associations and Chambers (TACs) and industry to continually review our suite of support measures and schemes for SMEs, to enable Singapore businesses and workers to thrive in a low-carbon future.
Continue Reading
